High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies

Bone Marrow Transplantation

Volumn 44, Issue 11, 2009, Pages 709-714

  Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Allogeneic; Autologous; HSCT; NK cell lymphoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE;

ADVANCED CANCER; AGGRESSIVE NK CELL LEUKEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; SKIN NEOPLASMS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 75049085234     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.239     Document Type: Review

References (42)

1. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. World Health Organization Classification of Tumours. IARC Press: Lyon, 2008, 285-288.
2. Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. IARC Press: Lyon, 2008, 276-277.
3. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/ leukemias. Semin Hematol 2003; 40: 221-232.
4. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 2186-2194.
5. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007; 139: 532-544.
6. Chim CS, Ooi GC, Shek TW, Liang R, Kwong YL. Lethal midline granuloma revisited: nasal T/natural-killer cell lymphoma. J Clin Oncol 1999; 17: 1322-1325.
7. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-4513.
8. Chim CS, Ma ES, Loong F, Kwong YL. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement. J Clin Pathol 2005; 58: 443-445.
9. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-829.
10. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-770.
11. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54-63.
12. Shikama N, Izuno I, Oguchi M, Gomi K, Sone S, Takei K et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997; 204: 467-470.
13. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
14. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59: 1127-1137.
15. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
16. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181-189.
17. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609-615.
18. Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
19. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.
20. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
21. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599-606.
22. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
23. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 2001; 19: 129-150.
24. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. World Health Organization Classification of Tumours. IARC Press: Lyon, 2008, 145-147.
25. Nawa Y, Takenaka K, Shinagawa K, Deguchi S, Matsumura N, Koyama S et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1321-1322.
26. Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma 2001; 42: 1297-1303.
27. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447-450.
28. Sanda T, Lida S, Ito M, Tsuboi K, Miura K, Harada S et al. Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy. Int J Hematol 2002; 75: 195-200.
29. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673-1676.
30. Koizumi K, Fujimoto K, Haseyama Y, Endo T, Nishio M, Yokota K et al. Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/Tcell lymphoma. Eur J Haematol 2004; 72: 140-144.
31. Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425-431.
32. Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ et al. Highdose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006; 37: 819-824.
33. Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet 1996; 347: 1124.
34. Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y et al. Successful treatment of Epstein-Barr virusassociated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1279-1282.
35. Makita M, Maeda Y, Takenaka K, Shinagawa K, Sunami K, Hiramatsu Y et al. Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol 2002; 76: 94-97.
36. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561-567.
37. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14: 1356-1364.
38. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
39. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBVpositive lymphomas in immunocompetent patients. Blood 2004; 104: 243-249.
40. Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006; 24: 28-32.
41. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 2005; 130: 860-868.
42. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.